All material subject to strictly enforced copyright laws. © 2022 Managing IP is part of the Euromoney Institutional Investor PLC group.

Germany: New liability for second medical use

The most recent decision of the Düsseldorf Appeal Court of January 9 2019 (Case No. I-2 U 27/18) in the legal dispute concerning the active substance fulvestrant contributes to solidifying the new liability requirement of "sufficient scope of use". This was formulated by the court for the first time in the Östrogenblocker decision of May 5 2017 (Case No. I-2 W 6/17). Subject to the proceedings was European patent EP1272195B1, which protects the use of fulvestrant in the preparation of a medicament for the treatment of a patient with breast cancer who was previously treated with an aromatase inhibitor and tamoxifen and where such previous treatment failed.

The appeal court upheld the Regional Court's decision (Case No: 4c O 46/17) which was in effect that a sufficient scope of use could not be proven by the patentee. In this context, the court formulated a two-step programme: firstly, it is a matter for the court to decide that there has been patent-compliant use to a sufficient extent and, secondly, that the generic company could not have been completely unaware of this fact. The probability of such a judicial finding being made increases with the number of patent-compliant use cases that have demonstrably occurred.

Further, the court stated that there could be particular outstanding benefits of the patented use compared to other therapeutic purposes which invite use of the preparation in accordance with the patent. Despite this jurisprudence in Germany, which, in a patentee-friendly manner, has come to a wide interpretation of the scope of protection of second medical use patents, the Düsseldorf Appeal Court has shown that the requirements for demonstrating these liability criteria can be stringent. But at least it is clear that a skinny label is no longer sufficient to avoid liability.

However, patent owners have an even harder time before the English courts. In the Warner-Lambert case concerning the drug pregabalin, the UK Supreme Court made clear in its decision of November 14 2018 (Case No. [2018] UKSC 56) that there is no liability on the part of the manufacturer based on foreseeability of the patented use. Especially Lord Sumption and Lord Reed recommended a new test, termed "outward presentation". According to this test, the only decisive factor for liability is how the product is presented after its manufacture. This is comparable with the German requirement of "manifest arrangement" ("sinnfällige Herrichtung"). Even if the Supreme Court addressed the question of infringement only in the context of an obiter dictum, it is now obvious that the UK court does not intend to follow Germany's patentee-friendly jurisprudential line.

steif.jpg
zorr-ulrike.jpg

Marco Stief

Ulrike Zorr


Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH

Elisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and ros bottom lb

More from across our site

ITC counsel explain why companies will continue to bring trade secret complaints to the venue and talk about how to tackle challenges
Google and Sonos patent war continues; CNIPA finishes first administrative patent trials; Oppo halts German sales after Nokia wins; Chugai settles Fresenius suit; Taylor Swift claims she never heard Playas Gon’ Play; AI can’t be inventor, says Federal Circuit
Brands and retailers should educate their marketing departments and get help from their sales teams so private label products don’t become a major problem
The UK government wants to stop local tech going to China, but tech transfer offices often have few options
Hubertus Schacht of the Munich Regional Court shares his thoughts on German SEP trends and their influence on the UPC
Trademark counsel applaud the EUIPO’s new filing system but reveal it has come with teething issues
The executive vice president of partnerships and acquisitions at the NPE explains how his company’s deal with Intel came to be
South Korean lawyers welcome the trademark guidelines but say the appellate board, courts, and other IP offices may not necessarily agree with the KIPO
Lawyers for Craig Wright will seek approval for expert evidence to help the England and Wales High Court understand how autism affects his character
IP counsel say rude judges can dent their confidence but that the effect on clients should not be underestimated
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree